SGMTSagimet Biosciences Inc
$6.53
$0.23
(3.40%)
Closed $6.53
$0.02
(0.31%)
After Hours
Reported EarningsMay 12
Mkt Cap$413.61M
Vol621,649.00
Fundamentals
Mkt Cap
$413.61M
Volume
-
52W High
$11.41
52W Low
$4.50
PE Ratio
-4.87
Avg. Volume
930,262.40
EPS (Annual)
-$1.58
Rev/Employee
$0.00
Earnings
May 12
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00
Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...
MarketBeat
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise
Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid...
MarketBeat
Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00
Guggenheim cut their target price on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday...
MarketBeat
Why Is Sagimet Biosciences Stock Trading Higher On Monday?
Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.read more...
Benzinga
Why Sagimet Biosciences Stock Is Soaring Today
Key PointsSagimet Biosciences is developing a handful of drugs, but its priority is acne therapies...
Nasdaq News: Markets
Biotech Breakthroughs and Energy Deals Send These Stocks Soaring
A powerful wave of dealmaking, clinical breakthroughs, and infrastructure buildouts is driving renewed momentum with companies spanning energy, biotech, semiconductors, and AI ecosystems delivering headline-making developments. $USEG, $QUIK, $KBLB, $YAAS, $SGMT, $DKI, $GLND
24-7 Market News
<
1
2
...
>